In the seven years between 1960 and 1967, psilocybin moved from an obscure ethnobotanical curiosity to a household word, became the subject of serious academic research, became the centerpiece of a public political controversy, and was effectively banned from legal research in the United States. The trajectory was extraordinary, the consequences were durable, and the actual history is more complicated than either its champions or its critics tend to remember.
This article is a cautious history. It traces what happened, who the principal figures were, what they actually did, and what the decade left behind. It does not endorse the 1960s research program as a model, and it does not dismiss it as wholly invalid. The aim is to render it accurately, because the cultural memory of the era continues to shape how psilocybin is discussed today, usually in a more flattering light than the record supports.
The starting conditions
By 1960, several things were already true. Albert Hofmann had isolated psilocybin from Psilocybe mexicana in 1958 and synthesized it pure in 1959. Sandoz Pharmaceuticals, the Swiss company where Hofmann worked, had begun distributing synthetic psilocybin to qualified researchers under the trade name Indocybin. R. Gordon Wasson's 1957 Life article had introduced magic mushrooms to a mass American audience, a story we tell in full in our profile of Wasson. Anthropological documentation of Mazatec ceremonial use was making its way into specialist literature.
What did not yet exist was a substantial Western research program. The previous decade had been dominated by LSD research, much of it conducted quietly in psychiatric, military, and intelligence settings. Psilocybin, as a newly available pharmaceutical-grade compound, offered academic researchers a way to study a powerful psychoactive substance without the intelligence-agency complications that surrounded LSD. It was into this opening that, in 1960, two new arrivals at Harvard University walked, Timothy Leary, a clinical psychologist who had recently spent a summer in Mexico and tried psilocybin mushrooms himself, and Richard Alpert, a developmental psychologist who would later be known as Ram Dass.
The Harvard Psilocybin Project
The Harvard Psilocybin Project began in late 1960 with institutional approval. Leary and Alpert proposed a program of academic research using Sandoz-supplied psilocybin to study what they called transcendental experience. The initial protocols were not radical by the standards of the era. Participants were screened, sessions were conducted in controlled environments, and outcomes were measured through interviews and questionnaires. Several of the project's early studies have a methodological structure that a contemporary reviewer would recognize.
The Concord Prison Experiment, conducted in 1961 and 1962, examined whether psilocybin sessions combined with psychotherapy could reduce recidivism among incarcerated men. The Marsh Chapel Experiment, often called the Good Friday Experiment, conducted by graduate student Walter Pahnke in 1962, was a placebo-controlled trial examining whether psilocybin could occasion mystical-type experiences in divinity students attending a Good Friday service. The latter has since been reanalyzed and partially replicated. The former, with hindsight, was methodologically thinner than its initial reports suggested. The Marsh Chapel study is worth noting because, despite its small size and the era's looser standards, it produced findings about the structure and durability of mystical-type experiences that have held up reasonably well as the modern research era has reopened similar questions.
The Concord Prison Experiment did not hold up. A six-year follow-up by Rick Doblin, published in 1998, found that the original reports of reduced recidivism were not supported by long-term outcome data, because the original study had counted parole violations and new incarcerations differently from the comparison group, inflating its apparent benefit. The lesson, by the time the reanalysis appeared, was already familiar. Enthusiastic early reports in psychedelic research often did not survive careful scrutiny, a pattern we return to in our guide on reading a clinical trial.
The departure from Harvard
The Harvard program did not collapse because of its science. It collapsed because Leary and Alpert lost institutional discipline. Within two years of the project's start they had begun providing psilocybin to undergraduates outside research protocols, had alienated colleagues who considered them insufficiently rigorous, and had failed to maintain the boundaries that distinguished academic research from informal advocacy.
By 1963 both men had been dismissed from Harvard, Leary for failing to fulfill teaching obligations and Alpert for providing psilocybin to undergraduates. The departures were public and acrimonious. Both men then moved into broader public roles outside academia. Leary became a counterculture figure. Alpert traveled to India, met his teacher Neem Karoli Baba, and reemerged as Ram Dass, the spiritual writer whose later book Be Here Now would sell millions of copies. The departures effectively ended serious academic psilocybin research at Harvard, and by elevating Leary into a public role, they accelerated the transition from psilocybin-as-research-topic to psilocybin-as-cultural-symbol.
The drift outside the lab
Between 1963 and 1968, psilocybin moved through several social contexts at once. Sandoz continued to supply pharmaceutical-grade psilocybin to qualified researchers worldwide, and a scientific literature continued to accumulate, though it was sparse compared with the LSD literature that dominated the era. Several smaller academic groups continued careful work, often outside the United States. At the same time, a recreational and quasi-spiritual culture of psilocybin use emerged in parallel, particularly in the United States.
The publication of books like Leary's The Psychedelic Experience in 1964, a guidebook framed around the Tibetan Book of the Dead, connected psilocybin use to broader spiritual and consciousness-exploration narratives. Underground cultivation of Psilocybe species began to be experimented with, though it would not become widely practical until the McKenna brothers' guide a decade later. The recreational use did not develop in isolation from the research. Leary increasingly treated the two as continuous, while many other researchers did not, and the split between scientifically careful work and culturally promotional work widened across the decade.
What the research era actually produced
The 1960s psilocybin literature, considered honestly, produced a mixed record, and some of it has survived as a useful foundation for contemporary research. Walter Pahnke's framework for measuring mystical-type experiences influenced the development of the Mystical Experience Questionnaire that contemporary trials still use. Researchers including Sidney Cohen and Eric Kast established baseline therapeutic protocols, for the treatment of alcoholism, end-of-life distress, and various conditions, that informed the modern Hopkins and NYU studies. And the conceptual articulation of set and setting, the idea that context is central to outcomes, was a 1960s contribution that has held up empirically, as we discuss in our dedicated piece on it.
Other aspects of the record have not survived scrutiny. Several of the most-cited treatment outcome studies reported clinical benefits that later reanalysis has weakened or refuted, the Concord Prison study being the clearest but not the only example. Many researchers offered broad theoretical extrapolations, about consciousness, personality transformation, and social change, that the evidence base of the time could not support. And the participants in most studies were unrepresentative, being graduate students, prisoners, terminally ill patients, or willing volunteers from psychedelic-curious networks, so generalization to other populations was rarely attempted and usually unwarranted. The honest summary is that the 1960s produced enough useful work to seed the contemporary research era, and enough overclaim to contribute substantially to the political backlash that froze the field.
The backlash
The Controlled Substances Act of 1970 placed psilocybin in Schedule I, the most restrictive category, defined as substances with high abuse potential and no accepted medical use. This classification was not based on a careful scientific review. It was the political consequence of half a decade of cultural drift, public alarm, and the perceived irresponsibility of figures like Leary. The 1971 United Nations Convention on Psychotropic Substances internationalized the prohibition, and the legal background to all of this is covered in our article on psilocybin's legal status worldwide.
By the early 1970s, legal psilocybin research in most of the world had become nearly impossible. Sandoz withdrew Indocybin from the market, and the pharmaceutical-grade supply that had enabled the previous decade of research effectively disappeared. Research grants dried up. Investigators who had built careers on this work moved into other fields or simply retired. A generation of researchers came of age in psychology and psychiatry without exposure to psychedelic research as a live topic, and by the 1980s psilocybin appeared in textbooks primarily as a historical curiosity or as a recreational drug whose legal classification spoke for itself. The freeze lasted roughly thirty years. The early signs of a thaw came in the mid-1990s, with regulatory approvals for tightly controlled human research at academic institutions, and the Hopkins program that opened in the early 2000s marked the beginning of the modern era.
Why the 1960s matters today
The contemporary research community lives in the shadow of the 1960s in several ways, some helpful and some less so. The helpful inheritance includes the substantial body of useful work that did get done despite the era's flaws. Concepts like set and setting, instruments like the Mystical Experience Questionnaire, and many of the protocol elements current trials use were first developed or articulated then, so the modern era did not have to reinvent the wheel.
The less helpful inheritance includes a default cultural memory that treats the 1960s as a coherent triumph of consciousness exploration. It was not. It was a chaotic period that produced some excellent work alongside considerable overclaim, and it ended badly for the field. Romanticizing it, as both psychedelic-movement writers and some popular journalism continue to do, tends to obscure the methodological caution that careful research requires. It also includes a public expectation that psychedelic research will deliver dramatic, transformative results, an expectation the 1960s set through its rhetoric. The modern era has produced findings worth taking seriously, but it has not delivered the wholesale transformations the earlier era promised, and the careful researchers working today are largely uncomfortable with the expectation that it should.
Figures worth knowing
Several figures from the era are worth knowing. Albert Hofmann, who lived from 1906 to 2008, was the Swiss chemist who isolated psilocybin and, separately, synthesized LSD, and who continued to write thoughtfully about both for decades after the research era ended, in works like LSD: My Problem Child, notably more measured than the public rhetoric of the time. Roger Heim, 1900 to 1979, was the French mycologist who accompanied Wasson on his Mexican expeditions, formally described several Psilocybe species, and collaborated with Hofmann on the chemical analysis that led to the isolation of psilocybin, his scientific contributions sometimes overshadowed by the more public figures.
Walter Pahnke, 1931 to 1971, was the Harvard graduate student whose Marsh Chapel experiment remains one of the more methodologically interesting studies of the era, and who died young, in a diving accident, before the political collapse of the field forced him to navigate its consequences. Sidney Cohen, 1910 to 1987, was a Los Angeles psychiatrist whose careful published work on the medical use of psychedelics, including his attention to adverse events, was unusually responsible for the era, and whose warning paper on the LSD reaction anticipated many of the safety concerns later used to justify scheduling. Stanislav Grof, born in 1931, was a Czech psychiatrist whose 1960s research with LSD and psilocybin informed his later work on what he called holotropic states, work whose clinical observations have influenced contemporary protocols even as his broader theoretical claims remain contested.
What this history asks us to hold
A few practical lessons emerge from a careful reading of the 1960s. First, premature institutional advocacy for the cultural use of a research substance can collapse the research itself. Leary's transition from researcher to advocate cost the field a generation. Second, the difference between rigorous and sloppy research in this domain is consequential, since several 1960s studies that did not survive scrutiny produced enthusiastic press at the time, and the same risk exists now. Third, the history is contested and worth reading from multiple angles, because the triumphalist accounts that emerged from the counterculture and the dismissive accounts that emerged from drug-war institutions are both incomplete. Several careful historians, particularly Jay Stevens, Erika Dyck, and Michael Pollan, have produced longer treatments worth engaging.
The 1960s gave the modern research era both its starting capital and many of its difficulties. Reading the history carefully is part of how the contemporary work can avoid repeating the era's mistakes. Reading the history at all is something the popular discussion of psilocybin still does too rarely, which is its own small argument for telling it plainly rather than fondly.